三种循环长链非编码RNA作为预测非小细胞肺癌的生物标志物。

Three circulating long non-coding RNAs act as biomarkers for predicting NSCLC.

作者信息

Tang Qingfeng, Ni Zhenhua, Cheng Zhuoan, Xu Jianhua, Yu Hui, Yin Peihao

出版信息

Cell Physiol Biochem. 2015;37(3):1002-9. doi: 10.1159/000430226. Epub 2015 Sep 23.

Abstract

BACKGROUND/AIMS: Circulating long non coding RNAs (lncRNAs) have emerged recently as major players in tumor biology and may be used for cancer diagnosis, prognosis, and as potential therapeutic targets. We explored circulating lncRNA as a predictor for the tumorigenesis of non-small-cell lung cancer (NSCLC).

METHODS

In this study, we applied a lncRNA microarray to screen for a potential biomarker for NSCLC, utilizing RT-PCR (ABI 7900HT). A multi-stage validation and risk score formula detection analysis was used.

RESULTS

We discovered that three lncRNAs (RP11-397D12.4, AC007403.1, and ERICH1-AS1) were up regulated in NSCLC, compared with cancer-free controls, with the merged area under the curve in the training and validation sets of 0.986 and 0.861. Furthermore, the positive predictive value and negative predictive value of the three merged factors were 0.72 and 0.87. We confirmed stable detection of the three lncRNAs by three cycles of freezing and thawing.

CONCLUSIONS

RP11-397D12.4, AC007403.1, and ERICH1-AS1 may be potential biomarkers for predicting the tumorigenesis of NSCLC in the future.

摘要

背景/目的：循环长链非编码RNA（lncRNA）最近已成为肿瘤生物学中的主要参与者，可用于癌症诊断、预后评估，并作为潜在的治疗靶点。我们探索了循环lncRNA作为非小细胞肺癌（NSCLC）肿瘤发生预测指标的可能性。

方法

在本研究中，我们应用lncRNA微阵列筛选NSCLC的潜在生物标志物，并利用逆转录-聚合酶链反应（ABI 7900HT）进行检测。采用多阶段验证和风险评分公式检测分析。

结果

我们发现，与无癌对照相比，三种lncRNA（RP11-397D12.4、AC007403.1和ERICH1-AS1）在NSCLC中上调，训练集和验证集的合并曲线下面积分别为0.986和0.861。此外，这三个合并因素的阳性预测值和阴性预测值分别为0.72和0.87。我们通过三个冻融循环证实了这三种lncRNA检测的稳定性。